Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Express Scripts
Accenture
McKinsey
Deloitte
AstraZeneca
Merck
Farmers Insurance
Cantor Fitzgerald

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,469,009

« Back to Dashboard

Summary for Patent: 6,469,009
Title: Pharmaceutical compositions for the treatment of rhinitis
Abstract:A pharmaceutical composition comprising a therapeutically effective amount of a mixture consisting essentially of (i) pseudoephedrine, an individual optical isomer or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivatives, an individual optical isomer or a pharmaceutically acceptable salt thereof.
Inventor(s): Van De Venne; Herman (Lasne, BE), Martin; Jean-Pierre (Montigny-le-Tilleul, BE)
Assignee: UCB, S.A. (Brussels, BE)
Application Number:08/629,144
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Dosage form;

Drugs Protected by US Patent 6,469,009

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
J And J Consumer Inc ZYRTEC-D 12 HOUR cetirizine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 021150-002 Nov 9, 2007 OTC Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,469,009

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,489,329 Pharmaceutical compositions for the treatment of rhinitis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,469,009

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1774097 ➤ Sign Up
Australia 723364 ➤ Sign Up
Brazil 9701686 ➤ Sign Up
Colombia 4820432 ➤ Sign Up
United Kingdom 2311940 ➤ Sign Up
United Kingdom 9706842 ➤ Sign Up
Guatemala 199700037 ➤ Sign Up
Mexico 9702532 ➤ Sign Up
New Zealand 314521 ➤ Sign Up
Panama 8426801 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Chinese Patent Office
Accenture
US Army
Express Scripts
Julphar
Harvard Business School
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot